Adalimumab

Therapeutic Drug Monitoring (TDM) of antitumor necrosis factor (TNF) such as Adalimumab has increased over time as doctors improve their treatment of IBD. Even if the medication is administered subcutaneously by the patient, there is a need to check trough levels before medication to ensure proper levels are maintained. However, obtaining results from previously available testing methods take days or even weeks.

ADL allows for true point-of-care testing of Adalimumab levels in under 5 minutes with finger stick blood. So during a standard visit with an IBD patient, a physician or technician can check their levels and adjust medication accordingly. During their very next injection, not weeks or months later.